Management of Hepatitis: Medications, Dosages, Routes, Side Effects, and Contraindications
Hepatitis A
Acute hepatitis A is a self-limited disease requiring only supportive care, as no virus-specific antiviral treatment has been proven effective 1. Management focuses on symptom relief and monitoring for complications.
Treatment Approach
- Supportive care only: High-calorie diet, bedrest if symptomatic, adequate hydration
- Avoid hepatotoxic medications (especially acetaminophen) and alcohol 2
- Hospitalization if unable to maintain oral intake due to nausea/vomiting or if mental status changes suggest fulminant hepatic failure 3
- Monitor for fulminant liver failure: Serial ALT, bilirubin, INR, and mental status assessment
- Liver transplantation may be lifesaving in rare cases of fulminant hepatic failure 1
Key Contraindications
No specific antiviral contraindications exist, but avoid all hepatotoxic substances during acute illness.
Hepatitis B
Acute Hepatitis B
Acute hepatitis B typically resolves spontaneously in 95% of immunocompetent adults and requires only supportive care 4. However, nucleoside analogs may be considered in specific circumstances.
Treatment Approach
- Supportive care is the primary management for most cases 1
- Consider lamivudine 100 mg orally daily in severe acute hepatitis B, though not subjected to controlled trials 1, 3
- Monitor for spontaneous clearance: Check HBsAg, HBV DNA, and ALT every 4-8 weeks for 6 months 2
- Initiate antiviral therapy if progression to chronic infection occurs (HBsAg positive >6 months)
Chronic Hepatitis B
Treatment of chronic hepatitis B aims to suppress viral replication and prevent progression to cirrhosis and hepatocellular carcinoma 5. High genetic barrier nucleoside analogs are preferred.
Recommended Medications & Dosages
First-line agents (high genetic barrier):
- Entecavir (ETV): 0.5 mg orally once daily (1 mg daily if lamivudine-experienced)
- Tenofovir disoproxil fumarate (TDF): 300 mg orally once daily
- Tenofovir alafenamide (TAF): 25 mg orally once daily
Alternative (lower barrier to resistance):
Route of Administration
All chronic HBV medications are administered orally, once daily.
Treatment Duration
- Indefinite therapy is typically required for most patients with chronic HBV
- Post-liver transplant prophylaxis: Continue nucleoside analog indefinitely, combined with hepatitis B immunoglobulin (HBIG) during anhepatic phase, with HBIG dosing adjusted to maintain anti-HBs levels 7
- Immunosuppression prophylaxis: Continue for at least 6-12 months after immunosuppressive therapy ends; extend to 18 months after B-cell depleting therapy (e.g., rituximab) 7
Side Effects
- TDF: Renal impairment, decreased bone mineral density, Fanconi syndrome
- TAF: Better renal and bone safety profile than TDF
- Entecavir: Generally well-tolerated; lactic acidosis (rare)
- Lamivudine: High rate of resistance with prolonged use (up to 70% at 5 years)
Contraindications
- Severe renal impairment (eGFR <30 mL/min): Requires dose adjustment for all nucleoside analogs
- Pregnancy considerations: TDF and TAF are preferred during pregnancy
- Decompensated cirrhosis: Not a contraindication; treatment is indicated
Special Populations
- Reactivation prevention: HBsAg-positive patients starting chemotherapy or immunosuppression should receive prophylactic nucleoside analog therapy 1
- Monitor HBV DNA every 3 months during immunosuppression in HBsAg-negative/anti-HBc-positive patients 7
Hepatitis C
Acute Hepatitis C
Treatment of acute hepatitis C should follow the same direct-acting antiviral (DAA) regimens as chronic infection, though monitoring for spontaneous clearance for 12-16 weeks is reasonable before initiating therapy 2.
Initial Management
- Monitor for spontaneous clearance: Check HCV RNA and ALT every 4-8 weeks for minimum 6 months 2
- Spontaneous clearance occurs in only 25% of acute cases 4
- If treatment is initiated early, monitor HCV RNA for at least 12-16 weeks to detect spontaneous clearance before starting therapy 2
- Counsel patients to avoid hepatotoxic drugs and alcohol; refer injection drug users to addiction medicine 2
Treatment Regimens
Use the same DAA regimens as chronic hepatitis C (see below).
Alternative (historical, less preferred):
- Pegylated interferon ± ribavirin for 16-24 weeks 2
Chronic Hepatitis C
All HCV-infected patients without contraindications should be considered for treatment, with priority given to those with advanced fibrosis (≥F3), decompensated cirrhosis, and pre/post-transplant patients 5. Modern DAA therapy achieves >90% cure rates.
Pangenotypic Regimens (All Genotypes 1-6)
Option 1: Sofosbuvir/Velpatasvir (Preferred)
- Dosage: Fixed-dose combination of sofosbuvir 400 mg + velpatasvir 100 mg orally once daily 8, 9
- Duration: 12 weeks for most patients 8, 9
- Treatment-naïve and treatment-experienced patients without cirrhosis or with compensated cirrhosis: 12 weeks without ribavirin 8
Option 2: Glecaprevir/Pibrentasvir
- Dosage: Fixed-dose combination of glecaprevir 300 mg + pibrentasvir 120 mg orally once daily 9
- Duration: 8-12 weeks depending on treatment history and cirrhosis status 9
Genotype-Specific Regimens
Genotype 1,4,5,6:
- Ledipasvir/Sofosbuvir: Fixed-dose combination of ledipasvir 90 mg + sofosbuvir 400 mg orally once daily for 12 weeks 9
- Grazoprevir/Elbasvir: Grazoprevir 100 mg + elbasvir 50 mg orally once daily for 12 weeks 8
Genotype 2:
- Sofosbuvir/Velpatasvir: 12 weeks without ribavirin 8
- Sofosbuvir/Daclatasvir: Sofosbuvir 400 mg + daclatasvir 60 mg orally once daily for 12 weeks without ribavirin 8
Genotype 3:
- Sofosbuvir/Velpatasvir: 12 weeks 8
- Sofosbuvir/Daclatasvir: 12 weeks with ribavirin for treatment-experienced or cirrhotic patients 8
Route of Administration
All DAAs are administered orally, once daily.
Ribavirin Dosing (When Added)
- Weight-based: 1000 mg daily (<75 kg) or 1200 mg daily (≥75 kg), divided into two doses 8
- Decompensated cirrhosis: Start at 600 mg daily and adjust based on tolerance 8
- Severe renal impairment: 200 mg daily if hemoglobin >10 g/dL 8
Side Effects
DAAs (generally well-tolerated):
- Sofosbuvir-based regimens: Headache, fatigue, nausea (common but mild)
- Protease inhibitors (grazoprevir, paritaprevir): Hyperbilirubinemia, hepatotoxicity
- Glecaprevir/pibrentasvir: Headache, fatigue, nausea
Ribavirin:
- Hemolytic anemia (dose-limiting): Monitor hemoglobin frequently; discontinue if <8.5 g/dL 8
- Fatigue, rash, pruritus
- Teratogenic: Absolute contraindication in pregnancy and partners of pregnant women
Pegylated Interferon (historical, rarely used):
- Flu-like syndrome, injection site reactions
- Neuropsychiatric disorders (depression, suicidal ideation)
- Cytopenias, autoimmune phenomena
- Thyroid dysfunction 5, 6
Contraindications
Sofosbuvir:
- Severe renal impairment (eGFR <30 mL/min/1.73 m²): Use with extreme caution; no dose recommendation available 5, 8
- Monitor renal function closely; discontinue immediately if deterioration occurs 8
Protease Inhibitors (paritaprevir, dasabuvir, asunaprevir):
- Decompensated cirrhosis (Child-Pugh B or C): Contraindicated due to markedly increased drug concentrations 5
Grazoprevir/Elbasvir:
- Cyclosporine co-administration: Contraindicated (15-fold increase in grazoprevir levels) 9, 10
- Strong CYP3A inducers (efavirenz, etravirine, carbamazepine, phenytoin, St. John's wort): Contraindicated 10
Ribavirin:
- Pregnancy: Absolute contraindication (teratogenic) 5
- Severe anemia (hemoglobin <10 g/dL at baseline)
- Severe cardiac disease
- Autoimmune hepatitis
- Uncontrolled psychiatric illness 5
Pegylated Interferon (historical):
- Decompensated cirrhosis
- Uncontrolled depression or psychiatric illness
- Uncontrolled autoimmune diseases
- Solid organ transplantation (except liver)
- Pregnancy
- Age ≤2 years
- Severe concurrent medical illness (poorly controlled hypertension, heart failure, significant coronary disease, poorly controlled diabetes, COPD) 5
Special Populations
Severe Renal Impairment (eGFR <30 mL/min) or Hemodialysis:
- Genotype 1a: Grazoprevir/elbasvir for 12 weeks with ribavirin 200 mg/day (if Hgb >10 g/dL) OR ritonavir-boosted paritaprevir/ombitasvir/dasabuvir for 12 weeks with ribavirin 200 mg/day 8
- Genotype 1b: Grazoprevir/elbasvir for 12 weeks without ribavirin OR ritonavir-boosted paritaprevir/ombitasvir/dasabuvir for 12 weeks without ribavirin 8
- Genotype 4: Ritonavir-boosted paritaprevir/ombitasvir for 12 weeks with ribavirin 200 mg/day OR grazoprevir/elbasvir for 12 weeks without ribavirin 8
- Treat in expert centers with multidisciplinary monitoring 8
Decompensated Cirrhosis (Child-Pugh B or C):
- Sofosbuvir/Velpatasvir: 12 weeks with weight-based ribavirin (start 600 mg daily, adjust for tolerance) 8
- Sofosbuvir/Ledipasvir (genotypes 1,4,5,6): 12 weeks with ribavirin 8
- Sofosbuvir/Daclatasvir: 12 weeks with ribavirin 8
- Avoid protease inhibitors (contraindicated) 5
- 24 weeks without ribavirin if ribavirin contraindicated or not tolerated 8
Post-Liver Transplant:
- Initiate treatment early (ideally after first 3 months post-transplant when patient stabilized) 8
- Genotype 1,4,5,6: Sofosbuvir/ledipasvir or sofosbuvir/daclatasvir for 12 weeks with weight-based ribavirin 8
- Genotype 2: Sofosbuvir/daclatasvir for 12 weeks with ribavirin 8
- Genotype 3: Sofosbuvir/daclatasvir for 24 weeks with ribavirin 8
- Monitor immunosuppressant levels closely; no dose adjustments needed except possibly everolimus 8
- Avoid protease inhibitors due to drug-drug interactions with immunosuppressants 8
HIV Coinfection:
- Sofosbuvir/velpatasvir: Compatible with most antiretrovirals 8
- Glecaprevir/pibrentasvir: Contraindicated with atazanavir and not recommended with other HIV protease inhibitors or efavirenz/etravirine/nevirapine 10
- Grazoprevir/elbasvir: Limited antiretroviral compatibility; can use with nucleotide RTIs, rilpivirine, raltegravir, dolutegravir, maraviroc, doravirine, bictegravir, cabotegravir 10
- Thorough drug-drug interaction assessment required before starting therapy 10
HCV-Negative Recipients of HCV-Viremic Organ Donors:
- Initiate DAA therapy as early as clinically possible (prophylactic/preemptive or reactive approach) 9
- Pangenotypic regimen required for prophylactic approach: Glecaprevir/pibrentasvir or sofosbuvir/velpatasvir for 12 weeks 9
- Avoid protease inhibitors in moderate-severe liver dysfunction 9
- Monitor calcineurin inhibitor levels closely; avoid elbasvir/grazoprevir with cyclosporine 9
Critical Drug-Drug Interactions
A thorough drug-drug interaction assessment is mandatory before starting DAA therapy and before adding any new medications during treatment 10. Key resources include www.hep-druginteractions.org.
High-Risk Interactions
- Amiodarone + sofosbuvir: Contraindicated (risk of severe bradycardia)
- Cyclosporine + grazoprevir/elbasvir: Contraindicated
- Strong CYP3A inducers (rifampin, carbamazepine, phenytoin, St. John's wort): Contraindicated with most protease inhibitors
- High-dose proton pump inhibitors: Contraindicated or not recommended with ledipasvir
- Certain statins (atorvastatin, simvastatin): Dose adjustments or monitoring required with protease inhibitors
- Tacrolimus levels: Monitor closely with all DAAs; 40-50% increase expected with grazoprevir/elbasvir 9
Common Pitfalls to Avoid
- Do not use sofosbuvir in severe renal impairment (eGFR <30) without careful consideration and close monitoring 5, 8
- Do not use protease inhibitors in decompensated cirrhosis 5
- Do not combine grazoprevir/elbasvir with cyclosporine 9
- Monitor hemoglobin frequently when using ribavirin; discontinue if <8.5 g/dL 8
- Ensure adequate contraception for 6 months after ribavirin discontinuation (both patient and partner) 5
- Check drug-drug interactions before prescribing DAAs, especially in HIV-coinfected patients 10
- Do not delay treatment in acute hepatitis C beyond 6 months if spontaneous clearance has not occurred 2
- Prioritize treatment in patients with advanced fibrosis (≥F3), decompensated cirrhosis, pre/post-transplant, and severe extrahepatic manifestations 5